Published in Gene Therapy Weekly, April 18th, 2002
Researchers in the U.S. say animal model experiments have demonstrated that a recombinant strain of herpes simplex virus (HSV), R7020, causes tumors to recede when combined with ionizing radiation in animals with grafted human hepatoma.
"The HSV recombinant virus R7020 is an attenuated virus designed as a candidate for immunization against both HSV-1 and HSV-2 infections," R. Weichselbaum and coauthors, University of Chicago, noted recently, adding, "It was extensively tested in an experimental animal...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2002-04-18)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.